Choroideremia: molecular mechanisms and development of AAV gene therapy-Reference-Cited by-同舟云学术

Choroideremia: molecular mechanisms and development of AAV gene therapy

Published:2018-06-22 Issue:7 Volume:18 Page:807-820
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Patrício Maria I¹²³,Barnard Alun R¹²³,Xue Kanmin¹²³,MacLaren Robert E¹²³

Affiliation:

1. Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

2. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Oxford, UK

3. Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Funder

Fight for Sight UK

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2018.1484448

Reference102 articles.

1. Clinical applications of retinal gene therapy

2. The molecular basis of human retinal and vitreoretinal diseases

3. Mauthner L. Ophthalmologische. Mittheilungen:2. Ein fall von choroideremie. Berichte des naturwissenschaftlichen-medizinischen verein innsbruck. Medical and Scientific Association Innsbruck. 1872. p. 191–197.

4. Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector

5. Natural History of the Central Structural Abnormalities in Choroideremia

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A hypomorphic variant of choroideremia is associated with a novel intronic mutation that leads to exon skipping;Ophthalmic Genetics;2024-01-26

2. Gene Augmentation of CHM Using Non-Viral Episomal Vectors in Models of Choroideremia;International Journal of Molecular Sciences;2023-10-16

3. AAV for Gene Therapy in Ocular Diseases: Progress and Prospects;Research;2023-01

4. Glial remodeling and choroidal vascular pathology in eyes from two donors with Choroideremia;Frontiers in Ophthalmology;2022-10-14

5. Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5;American Journal of Ophthalmology;2022-08